Martins Silvia S, Sarvet Aaron, Santaella-Tenorio Julian, Saha Tulshi, Grant Bridget F, Hasin Deborah S
Department of Epidemiology, Mailman School of Public Health, Columbia University, New York, New York.
Laboratory of Epidemiology and Biometry, Division of Intramural Clinical and Biological Research, National Institute on Alcohol Abuse and Alcoholism, National Institutes of Health, Rockville, Maryland.
JAMA Psychiatry. 2017 May 1;74(5):445-455. doi: 10.1001/jamapsychiatry.2017.0113.
Heroin use is an urgent concern in the United States. Little is know about the course of heroin use, heroin use disorder, and associated factors.
To examine changes in the lifetime prevalence, patterns, and associated demographics of heroin use and use disorder from 2001-2002 to 2012-2013 in 2 nationally representative samples of the US adult general population.
DESIGN, SETTING, AND PARTICIPANTS: This survey study included data from 43 093 respondents of the 2001-2002 National Epidemiologic Survey on Alcohol and Related Conditions (NESARC) and 36 309 respondents of the 2012-2013 NESARC-III. Data were analyzed from February 2 to September 15, 2016.
Lifetime heroin use and DSM-IV heroin use disorder.
Among the 79 402 respondents (43.3% men; 56.7% women; mean [SD] age, 46.1 [17.9] years), prevalence of heroin use and heroin use disorder significantly increased from 2001-2002 to 2012-2013 (use: 0.33% [SE, 0.03%] vs 1.6% [SE, 0.08%]; disorder: 0.21% [SE, 0.03%] vs 0.69% [SE, 0.06%]; P < .001). The increase in the prevalence of heroin use was significantly pronounced among white (0.34% [SE, 0.04%] in 2001-2002 vs 1.90% [SE, 0.12%] in 2012-2013) compared with nonwhite (0.32% [SE, 0.05%] in 2001-2002 vs 1.05% [SE, 0.10%] in 2012-2013; P < .001) individuals. The increase in the prevalence of heroin use disorder was more pronounced among white individuals (0.19% [SE, 0.03%] in 2001-2002 vs 0.82% [SE, 0.08%] in 2012-2013; P < .001) and those aged 18 to 29 (0.21% [SE, 0.06%] in 2001-2002 vs 1.0% [0.17%] in 2012-2013; P = .01) and 30 to 44 (0.20% [SE, 0.04%] in 2001-2002 vs 0.77% [0.10%] in 2012-2013; P = .03) years than among nonwhite individuals (0.25% [SE, 0.04%] in 2001-2002 vs 0.43% [0.07%] in 2012-2013) and older adults (0.22% [SE, 0.04%] in 2001-2002 vs 0.51% [SE, 0.07%] in 2012-2013). Among users, significant differences were found across time in the proportion of respondents meeting DSM-IV heroin use disorder criteria (63.35% [SE, 4.79%] in 2001-2001 vs 42.69% [SE, 2.87%] in 2012-2013; P < .001). DSM-IV heroin abuse was significantly more prevalent among users in 2001-2002 (37.02% [SE, 4.67%]) than in 2012-2013 (19.19% [SE, 2.34%]; P = .001). DSM-IV heroin dependence among users was similar in 2001-2002 (28.22% [SE, 3.95%]) and in 2012-2013 (25.02% [SE, 2.20%]; P = .48). The proportion of those reporting initiation of nonmedical use of prescription opioids before initiating heroin use increased across time among white individuals (35.83% [SE, 6.03%] in 2001-2002 to 52.83% [SE, 2.88%] in 2012-2013; P = .01).
The prevalence of heroin use and heroin use disorder increased significantly, with greater increases among white individuals. The nonmedical use of prescription opioids preceding heroin use increased among white individuals, supporting a link between the prescription opioid epidemic and heroin use in this population. Findings highlight the need for educational campaigns regarding harms related to heroin use and the need to expand access to treatment in populations at increased risk for heroin use and heroin use disorder.
海洛因使用在美国是一个紧迫问题。人们对海洛因使用过程、海洛因使用障碍及相关因素了解甚少。
在2个具有全国代表性的美国成年普通人群样本中,研究2001 - 2002年至2012 - 2013年期间海洛因使用及使用障碍的终生患病率、模式和相关人口统计学特征的变化。
设计、地点和参与者:这项调查研究纳入了2001 - 2002年全国酒精及相关疾病流行病学调查(NESARC)的43093名受访者以及2012 - 2013年NESARC - III的36309名受访者的数据。数据于2016年2月2日至9月15日进行分析。
终生海洛因使用和DSM - IV海洛因使用障碍。
在79402名受访者中(男性占43.3%;女性占56.7%;平均[标准差]年龄为46.1[17.9]岁),2001 - 2002年至2012 - 2013年期间,海洛因使用和海洛因使用障碍的患病率显著增加(使用:0.33%[标准误,0.03%]对1.6%[标准误,0.08%];障碍:0.21%[标准误,0.03%]对0.69%[标准误,0.06%];P<0.001)。与非白人(2001 - 2002年为0.32%[标准误,0.05%],2012 - 2013年为1.05%[标准误,0.10%];P<0.001)相比,白人中海洛因使用患病率的增加更为显著(2001 - 2002年为0.34%[标准误,0.04%],2012 - 2013年为1.90%[标准误,0.12%])。白人个体(2001 - 2002年为0.19%[标准误,0.03%],2012 - 2013年为0.82%[标准误,0.08%];P<0.001)、18至29岁人群(2001 - 2002年为0.21%[标准误,0.06%],2012 - 2013年为1.0%[0.17%];P = 0.01)以及30至44岁人群(2001 - 2002年为0.20%[标准误,0.04%],2012 - 2013年为0.77%[0.10%];P = 0.03)中海洛因使用障碍患病率的增加比非白人个体(2001 - 2002年为0.25%[标准误,0.04%],2012 - 2013年为0.43%[0.07%])和老年人(2001 - 2002年为0.22%[标准误,0.04%],2012 - 2013年为0.51%[标准误,0.07%])更为明显。在使用者中,符合DSM - IV海洛因使用障碍标准的受访者比例在不同时间存在显著差异(2001 - 2001年为63.35%[标准误,4.79%],2012 - 2013年为42.69%[标准误,2.87%];P<0.001)。2001 - 2002年使用者中DSM - IV海洛因滥用的患病率(37.02%[标准误,4.67%])显著高于2012 - 2013年(19.19%[标准误,2.34%];P = 0.001)。2001 - 2002年和2012 - 2013年使用者中DSM - IV海洛因依赖情况相似(2001 - 2002年为28.22%[标准误,3.95%],2012 - 2013年为25.02%[标准误,2.20%];P = 0.48)。在白人个体中,报告在开始使用海洛因之前开始非医疗使用处方阿片类药物的比例随时间增加(2001 - 2002年为35.83%[标准误,6.03%],2至2012 - 2013年为52.83%[标准误,2.88%];P = 0.01)。
海洛因使用和海洛因使用障碍的患病率显著增加,白人中的增加更为明显。白人个体在使用海洛因之前非医疗使用处方阿片类药物的情况有所增加,这支持了该人群中处方阿片类药物流行与海洛因使用之间的联系。研究结果凸显了开展关于海洛因使用危害的教育活动的必要性,以及扩大对海洛因使用和海洛因使用障碍风险增加人群的治疗可及性的必要性。